image description  

Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and meta-analysis

  • 2017/11/21
Type of publication
  • Articles
  • Lopez
  • A.L.; Deen
  • J.; Azman
  • A.S.; Luquero
  • F.J.; Kanungo
  • S.; Dutta
  • S.; von
  • Seidlein L.; Sack
  • D.A.
  • Vaccination

In addition to improved water supply and sanitation, the two-dose killed oral cholera vaccine (OCV) is an important tool for the prevention and control of cholera. We aimed to document the immunogenicity and protection (efficacy and effectiveness) conferred by a single OCV dose against cholera. The meta-analysis showed an estimated 73% and 77% of individuals seroconverted to the Ogawa and Inaba serotypes, respectively, after an OCV first dose. The estimates of single-dose vaccine protection from available studies are 87% at 2 months decreasing to 33% at 2 years. Current immunologic and clinical data suggest that protection conferred by a single dose of killed OCV may be sufficient to reduce short-term risk in outbreaks or other high-risk settings, which may be especially useful when vaccine supply is limited. However, until more data suggests otherwise, a second dose should be given as soon as circumstances allow to ensure robust protection.